Shopping Cart
Remove All
Your shopping cart is currently empty
UCUF-965
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T218625 Copy Product Info
🥰Excellent
UCUF-965 is a positive allosteric modulator of CXCR4. It enhances CXCL12-mediated β-arrestin recruitment and cAMP signaling pathways, thereby activating lymphoblast migration and inducing calcium influx without binding to the orthosteric CXCL12-binding site on CXCR4. In fibroblasts, UCUF-965 reduces levels of miR-15b and miR-29a while increasing miR-146a. Additionally, UCUF-965 promotes angiogenesis and accelerates wound healing in diabetic mice, making it useful for research into diabetic wound healing disorders.
UCUF-965
Cas No. 2965316-77-0
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | UCUF-965 is a positive allosteric modulator of CXCR4. It enhances CXCL12-mediated β-arrestin recruitment and cAMP signaling pathways, thereby activating lymphoblast migration and inducing calcium influx without binding to the orthosteric CXCL12-binding site on CXCR4. In fibroblasts, UCUF-965 reduces levels of miR-15b and miR-29a while increasing miR-146a. Additionally, UCUF-965 promotes angiogenesis and accelerates wound healing in diabetic mice, making it useful for research into diabetic wound healing disorders. |
| In vitro | UCUF-965, within the concentration range of 0.1-10 μM, enhances the recruitment of β-arrestin with an EC50 of 0.02 μM. It functions as a partial agonist of CXCR4-mediated cAMP inhibition in CXCR4-overexpressing CHO cells, with an EC50 of 0.05 μM. UCUF-965, after a 3-hour exposure, induces migration in the human lymphoblastic cell line CEM-CCRF via CXCR4 activation, presenting an EC50 of 0.4 μM. At a concentration of 10 μM, UCUF-965 facilitates CXCR4-mediated calcium influx in the CEM-CCRF cell line. Additionally, a 24-hour treatment with UCUF-965, at 0.1-10 μM, modulates the expression of wound healing-related microRNAs in both diabetic and non-diabetic mouse fibroblasts, decreasing the levels of miR-15b and miR-29a while increasing the level of miR-146a. |
| In vivo | UCUF-965 (10 μM; intradermal injection; single administration) reduces wound healing time in diabetic mice by 36% and enhances angiogenesis. |
| Molecular Weight | 405.52 |
| Formula | C22H23N5OS |
| Cas No. | 2965316-77-0 |
| Smiles | N=1N=C(C=2C=CC=CC2OCC)N3N=C(C=4C=CC(=CC4)N5CCCC5)CSC13 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: UCUF-965 in vivo | UCUF-965 in vitro | UCUF-965 formula | UCUF-965 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.